SLC5A2 and type 2 diabetes mellitus: Large randomized controlled trials of SGLT2-i, empagliflozin (EMPA-REG OUTCOME), canagliflozin (CANVAS PROGRAM), and dapagliflozin (DECLARE-TIMI 58) have proven their efficacy in cardiovascular outcome in patients with T2D and high cardiovascular risk or established cardiovascular disease [6,7,8].